Aflac Shorts Retreat Sharply Before Wednesday's Print

AFL enters Wednesday's earnings release with short sellers cutting positions at a pace well outside the norm, while its closest insurance peers are mostly treading water.

Short interest in Aflac has fallen 12.3% over the past week, a move the editorial brief flags as 2.2 standard deviations below the company's typical weekly change. That brings the short position to roughly 1.9% of the free float, a low level even by AFL's own standards. The pullback was concentrated: shares short dropped from around 11.1 million in mid-October to 9.7 million by October 29, most of that decline arriving in a single session around October 23. Borrowing conditions tell the same story. The cost to borrow has fallen 42% over the past week to just 0.22%, and availability is essentially unconstrained, with shares available to lend far exceeding current demand. This is not a stock where the lending market is signaling any stress.

AFL outperformed its peer group on the week, gaining 2.8% while the median for its closest correlates was closer to flat. CB and AFG posted modest gains of around 2.5% and 2.2% respectively, but HIG fell 3% and ORI slipped 1%. AFL's relative strength sits alongside a put/call ratio of 0.49, slightly below its 20-day average of 0.53, which points to options positioning that is more relaxed than usual rather than defensively positioned into the report.

The analyst picture is less settled. Coverage has been dominated by target cuts in recent weeks, with Wells Fargo, Keefe Bruyette, and Mizuho all trimming targets while holding their ratings unchanged. JP Morgan moved the other way, nudging its target to $119. The mean target of around $117 sits below AFL's current price of $123.89, a gap that reflects genuine disagreement about the near-term trajectory. The core dispute is Japan. Japan's benefit ratio ran to 63.4% year-to-date through the last print, above the top of the company's 60-63% guide, and currency headwinds have complicated the path to its JPY 80 billion sales target for the year. Against that, the restructuring of a roughly $4.8 billion investment portfolio is expected to add around $50 million of annual pre-tax net investment income over time, and management has pointed to improving cross-sell momentum in cancer and medical products as a reason for optimism on 2026 Japan sales.

Japan Post Holdings, Aflac's 10% shareholder, has been a steady seller through October under a pre-arranged 10b5-1 plan, filing sales worth a combined $13.5 million across October 12 to 15. Because these trades run on a scheduled plan, they carry limited signal about Japan Post's view of the upcoming print. The 13D/G register shows Japan Post's stake was last disclosed at 10.15%, and Vanguard restructured its holding earlier this year; as always with these disclosures, stakes are as-last-reported around the 5% threshold.

The November 4 print will test whether Japan's benefit ratio has begun to track back toward guidance and whether U.S. premium trends can stabilise, given management's acknowledgment that growth would likely miss the 3-6% target range set earlier in the year.